BTAI
Bioxcel Therapeutics·NASDAQ
--
--(--)
--
--(--)
4.67 / 10
Netural
Sentiment is neutral (4.67/10) while fund‑flow scores 7.71/10, indicating solid liquidity but overall negative inflow trends except medium‑size investors. Analyst consensus is bullish (2 Strong Buy), yet historical win rates are low (0%–16.7%). Caution advised.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
100%
Buy
0%
Hold
0%
Sell
0%
Strong Sell
0%
Date2026-03-17
InstitutionRodman & Renshaw
Times predicted1
Historical Win Rate0.0%
What is the analyst consensus for BTAI?
- BTAI holds a Bearish analyst rating, with 100% of experts assigning a Strong Buy grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 4.67/10 (Netural).
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
